Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY: PFE )

25.76 -0.41 (-1.57%)
Streaming Delayed Price Updated: 2:26 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
Exposures COVID-19
Precision Medicine M&A is Transforming the Future of the Biotech Industry
Via AB Newswire
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug. 
Via Investor's Business Daily
How Is The Market Feeling About Pfizer?
Via Benzinga
Is It Too Late to Buy Pfizer Stock?
It's no secret that the last year has been punishing. 
Via The Motley Fool
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Check Out What Whales Are Doing With PFE
Via Benzinga
3 Stocks to Sell as Ozempic Surges in Popularity
GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity. 
Via InvestorPlace
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
Via Investor's Business Daily
Exposures Product Safety
What's Going On With Pfizer On Thursday? Pharma Giant's Shares Tick Lower
Pfizer Inc. reported that its Phase 3 CIFFREO study on Duchenne muscular dystrophy (DMD) gene therapy did not meet its primary effectiveness goal. Despite efforts to improve motor functions in boys... 
Via Benzinga
Exposures COVID-19
3 Ultra-High-Yield Dividend Stocks Billionaires Are Sinking Their Teeth Into
Prominent billionaire money managers are piling into three industry-leading businesses with supercharged yields ranging from 6% to 15.1%! 
Via The Motley Fool
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
From Pfizer Inc.
Via Business Wire
3 Hidden-Gem Value Stocks to Buy and Never Let Go
Here are three top hidden-gem value stocks long-term investors would do well to consider on any meaningful dips moving forward. 
Via InvestorPlace
7 Recession-Proof Stocks to Buy Now for Peace of Mind
Dive into the fundamentals behind the resilience of recession-proof stocks and the performance indicators driving their success. 
Via InvestorPlace
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. 
Via InvestorPlace
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
After the FDA's authorization of a Covid19 booster shot, you may want to consider adding these vaccine stocks to your portfolio. 
Via InvestorPlace
Exposures Product Safety
Billionaires Are Buying These 2 Ultra-High-Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?
These high-yield dividend payers have what it takes to pump up your portfolio's passive income stream. 
Via The Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These pharma and biotech players could become long-term winners. 
Via The Motley Fool
Masters In Trading - Saturday, June 8
In this video, I review the most recent trading session. I also discuss what a trader's 
Via Talk Markets
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
These stocks offer great dividends and more. 
Via The Motley Fool
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1. 
Via Benzinga
Exposures COVID-19 Product Safety
2 Dividend Stocks Billionaires Are Buying: Should You?
That's not a bad crowd to follow when investing in stocks. 
Via The Motley Fool
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
Via AB Newswire
Novavax Stock’s Recent Surge and Future Potential
Novavax's future hinges on its ability to translate recent stock market momentum into sustained financial performance. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Product Safety Supply Chain
Is a Giant Short Squeeze Brewing in Novavax (NVAX) Stock?
Novavax will be ready for the new Covid-19 JN.1 variants in September, but NVAX stock is also undergoing a short squeeze. 
Via InvestorPlace
Exposures COVID-19
Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move
Novavax also said it's planning to launch a JN.1-focused Covid booster shot this fall. 
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
Via AB Newswire
Why Is Novavax (NVAX) Stock Up 20% Today?
Novavax continues to march higher in its recovery efforts, with its latest vaccine announcement lifting NVAX stock. 
Via InvestorPlace
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.